KYNTRA BIO, INC.: ARMISTICE CAPITAL, LLC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Armistice Capital, LLC amended its Schedule 13G stake filing for Kyntra Bio, Inc., disclosing the change to the SEC under accession number 0001172661-26-005240. The filing updates Armistice's previously reported beneficial ownership position in the company. The amendment signals a change in the investor's holdings, though the filing excerpt did not specify the exact share count or percentage. Investors will watch for the full 13G disclosure to see whether Armistice increased, trimmed or maintained its stake.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
KYNTRA BIO, INC., ARMISTICE CAPITAL, LLC